

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

EXTENSION OF LONG STOP DATE DISCLOSEABLE TRANSACTION

Reference is made to the announcement of TATA Health International Holdings Limited (the “**Company**”) dated 29 June 2021 (the “**Announcement**”) in relation to, among other things, the Investment. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

It has been agreed in principle that the Long Stop Date will be extended to 27 August 2021.

Save and except for the aforesaid extension of the Long Stop Date, all other terms and conditions of the Investment and Shareholders Agreement, the Share Purchase Agreement and the Sub-Licensing Agreement Term Sheet remain unchanged and in full force and effect in all respects.

By order of the Board
TATA Health International Holdings Limited
Yang Jun
Chairman

Hong Kong, 10 August 2021

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jun and Mr. Lai Wenjing; four non-executive Directors, namely, Mr. Lin Zheming, Mr. Lin Jun, Mr. Chu Chun Ho, Dominic and Mr. Chen Anhua and three independent non-executive Directors, namely, Mr. Xie Rongxing, Prof. Yan Haifeng and Ms. Tan Yuying.